AGIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AGIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-12-11), Agios Pharmaceuticals's share price is $43.37. Agios Pharmaceuticals's Tangible Book per Share of Sep. 2024 for the quarter that ended in Sep. 2024 was $28.53. Hence, Agios Pharmaceuticals's Price to Tangible Book Ratio of today is 1.52.
The historical rank and industry rank for Agios Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:
During the past 13 years, Agios Pharmaceuticals's highest Price to Tangible Book Ratio was 10.29. The lowest was 1.08. And the median was 4.90.
A closely related ratio is called PB Ratio. As of today, Agios Pharmaceuticals's share price is $43.37. Agios Pharmaceuticals's Book Value per Sharefor the quarter that ended in Sep. 2024 was $28.53. Hence, Agios Pharmaceuticals's P/B Ratio of today is 1.52.
The historical data trend for Agios Pharmaceuticals's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agios Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Price-to-Tangible-Book | Get a 7-Day Free Trial | 5.10 | 7.52 | 1.38 | 1.40 | 1.54 |
Agios Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Price-to-Tangible-Book | Get a 7-Day Free Trial | 1.56 | 1.54 | 2.23 | 3.71 | 1.56 |
For the Biotechnology subindustry, Agios Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Agios Pharmaceuticals's Price-to-Tangible-Book falls into.
Agios Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:
Price to Tangible Book | = | Share Price | / | Tangible Book per Share (Q: Sep. 2024 ) |
= | 43.37 | / | 28.527 | |
= | 1.52 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price to Tangible Book | = | Market Cap | / | Tangible Equity | ||||
= | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) |
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Agios Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Rahul D. Ballal | director | 116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116 |
Washburn Theodore James Jr. | officer: Principal Accounting Officer | C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
James William Burns | officer: Chief Legal Officer | C/O AGIOS PHARMACEUTICALS, 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
Cecilia Jones | officer: Chief Financial Officer | C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421 |
Brian Goff | director, officer: Chief Executive Officer | C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510 |
Sarah Gheuens | officer: Chief Medical Officer | C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
Jacqualyn A Fouse | director | C/O DICK'S SPORTING GOODS, 345 COURT STREET, CORAOPOLIS PA 15108 |
Kaye I Foster-cheek | director | JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933 |
David P Schenkein | director, 10 percent owner, officer: Chief Executive Officer | C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Tsveta Milanova | officer: Chief Commercial Officer | C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY SREET, CAMBRIDGE MA 02139 |
Jeffrey D Capello | director | C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912 |
Catherine E. Owen | director | 1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067 |
Cynthia Smith | director | 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
Richa Poddar | officer: Chief Commercial Officer | C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
Carman Alenson | officer: Principal Accounting Officer | 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
From GuruFocus
By GuruFocus Research • 08-01-2024
By GuruFocus Research • 06-07-2024
By Marketwired • 08-01-2024
By GuruFocus News • 11-01-2024
By Marketwired • 10-23-2024
By GuruFocus News • 11-01-2024
By GlobeNewswire • 08-06-2024
By Marketwired • 09-11-2024
By Marketwired • 10-31-2024
By GuruFocus Research • 05-03-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.